Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Non-small Cell Lung Cancers
Interventions: DRUG: Adagrasib|DRUG: Olaparib
Sponsor: M.D. Anderson Cancer Center
Collaborators: Mirati Therapeutics Inc.